



SUVEN Life Sciences

Communication to investors **June 2016**

10-Aug-16

2016-17 Q1 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

FINANCIAL QUICK VIEW

Quarter 1 – June 2016



	Q1-FY17 to Q4-FY16	Q1-FY17 to Q1-FY16
Growth in Revenue	-20.81%	29.54%
Growth in PAT	-12.38%	58.12%
Growth in EBIDTA	-8.56%	56.34%
Growth Pre-R&D EBIDTA	-9.51%	34.40%
Increase in R&D costs	-12.47%	-7.82%
R&D cost to revenue	10.67%	


MAJOR PROFITABILITY RATIOS



	30 Jun 2016	31 Mar 2016	30 Jun 2015
PAT to Income	23.65%	21.38%	19.38%
EBIDTA to Income	34.80%	30.14%	28.84%
Cash Flow to Income	27.14%	24.13%	22.11%
Pre-R&D EBITDA to Income	45.47%	39.79%	43.83%



INCOME COMPARISON




10-Aug-16

2016-17 Q1 results



PROFIT COMPARISON




10-Aug-16

2016-17 Q1 results



EBIDTA COMPARISON




10-Aug-16

2016-17 Q1 results



R & D – EXPENDITURE




10-Aug-16

2016-17 Q1 results



PRE-R&D EBIDTA




10-Aug-16

2016-17 Q1 results



PRE-R&D CASHFLOW



10-Aug-16

2016-17 Q1 results



Financial Snapshot

All figures are in INR Million, other than ratios and EPS

	Q1 Cur qtr	Q4 Pre qtr	Growth %	PreYrqr	Growth %
Income	1,377.24	1,739.25	-20.81%	1,063.16	29.54%
Pre-R&D EBITDA	626.21	692.02	-9.51%	465.40	34.40%
Pre-R&D EBITDA Margin	45.47%	39.79%		43.83%	
EBITDA	479.31	524.20	-8.56%	306.58	56.34%
EBITDA Margin	34.80%	30.14%		28.84%	
EBIT	431.25	476.22	-9.44%	277.53	55.39%
EBIT Margin	31.31%	27.38%		26.10%	
Financing costs	15.95	16.75		10.35	
Taxes	89.54	87.69		61.17	
Net Profit after tax	325.76	371.78		206.02	
NP Margin	23.65%	21.38%		19.38%	
EPS (basic & diluted not annualised)	2.55	2.91		1.61	
Paid up share capital (One Rupee Share)	127.28	127.28		127.28	
Depreciation	48.05	47.98		29.05	
R&D expenses	146.90	167.82	-12.47%	159.36	-7.82%

10-Aug-16

2016-17 Q1 results



News Release

- Ongoing SUVN-502 Phase 2A clinical trial, indicated for patients with moderate Alzheimer's in 69 investigator sites in USA.
- SUVN-D4010 Phase 1 clinical trial completed successfully in USA.
- During the period Suven secures 11 product patents covering India, South Africa, Israel, Mexico, Canada, Honk Kong, Europe, Eurasia, Macau and New Zealand.
- Suven's Pashamylaram unit successfully completed US FDA inspection.
- Suven participated in Annual Investors Conference – Trinity India 2016, held in Mumbai in May 2016
- Suven presented in Alzheimer's conference, AAIC>2016 held in Toronto, Canada in July 2016.